Sanofi Reports Results of Biosimilar Insulin Lispro Demonstrated Similar PK and PD Parameters to Humalog
Shots:
- The P-I study evaluates SAR342434 (0.3-U/kg, SC) vs insulin lispro (Humalog) in 36 healthy male patients with T1D or T2D
- The results showed that SAR-Lis had similar PK exposure and glucose pharmacodynamic activity compared with Japanese-approved insulin lispro formulation supporting the use of SAR-Lis as a biosimilar product, no serious AEs, AEs of special interest, or TEAEs leading to treatment discontinuation
- Additionally, a few clinically significant abnormalities in laboratory tests and ECG parameters were observed with no notable difference b/w SAR-Lis and the reference Humalog. SAR-Lis was the first insulin lispro biosimilar authorized in the EU in 2017 and in Japan in 2020
Ref: Centre for Biosimilars | Image: Sanofi
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
